Aurobindo Pharma eyeing inorganic growth opportunities

27 Nov 2017 Evaluate

Aurobindo Pharma is looking at inorganic growth opportunities in Eastern Europe and other geographies for deeper market penetration and to secure newer technologies. Apart from acquisitions, the company is also keen to expand its product portfolio in the US and Western European markets with high-value drugs.

The company has filed a total of 90 injectable ANDAs as of end September, of which 51 have already been approved - two tentative approvals and the rest are under review with USFDA. The company expects injectable business, which has already ramped up well, to grow by at least 40% this fiscal.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.




Aurobindo Pharma Share Price

1087.10 -27.80 (-2.49%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.